(1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methyl 2-aminoacetate | 1026200-06-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methyl 2-aminoacetate
• 英文别名: [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methyl 2-aminoacetate
• CAS: 1026200-06-5
• 化学式: C₂₄H₂₆ClN₇O₂
• 分子量: 479.969
• InChiKey: RBDYMYZQHTXNFX-UHFFFAOYSA-N

物化性质

• 沸点：
  697.5±65.0 °C(Predicted)
• 密度：
  1.37±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  34
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  125
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Ester Derivatives of Losartan, Methods for Their Preparation, and Uses Thereof
  申请人：Wang Jianmin

  公开号：US20100184814A1

  公开（公告）日：2010-07-22

  The present invention relates to compounds represented by the formula (I) as prodrugs of the formula (II) (Losartan) and their salts, solvates, hydrates, polymorphs, optical isomers, enantiomers, and pharmaceutical compositions comprising these compounds and methods of preparing them and administering them for the treatment of circulatory diseases such as hypertension, congestive heart failure, angina, and the like.

  本发明涉及由式(I)表示的化合物，作为式(II)（洛卡特普）的前药及其盐、溶剂合物、水合物、多晶形态、光学异构体、对映异构体，以及包含这些化合物的药物组合物，以及制备它们和用于治疗循环系统疾病如高血压、充血性心力衰竭、心绞痛等的方法。
• [EN] CRYSTALLIZATION METHOD AND BIOAVAILABILITY<br/>[FR] PROCÉDÉ DE CRISTALLISATION ET BIODISPONIBILITÉ
  申请人：THAR PHARMACEUTICALS INC

  公开号：WO2017049294A1

  公开（公告）日：2017-03-23

  Preparation and in vitro and in vivo characterization of novel forms of active pharmaceutical ingredients, suitable for pharmaceutical compositions in drug delivery systems for humans.

  准备并进行体外和体内特性评价，研究新型活性药物成分的形式，适用于人体药物输送系统中的药物组合。
• [EN] TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF<br/>[FR] CONJUGUÉS CIBLÉS, PARTICULES ET PRÉPARATIONS ASSOCIÉES
  申请人：BLEND THERAPEUTICS INC

  公开号：WO2016004043A1

  公开（公告）日：2016-01-07

  Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, comprising conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.

  包括纳米颗粒和微粒子在内的粒子以及其制剂，包括将活性药剂（如治疗、预防或诊断药剂）与靶向基团通过连接剂结合的共轭物。这些设计可以提供改善活性药剂的时间空间传递和/或改善生物分布的效果。提供了制备共轭物、粒子和制剂的方法。提供了向需要的受试者（例如治疗或预防癌症或传染病）施用制剂的方法。
• [EN] HYDROXYPHENYL-SUBSTITUTED PYRROLO[2,3d]PYRIMIDINE DERIVATIVES, PROCESSES AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS<br/>[FR] DÉRIVÉS DE PYRROLO[2,3D]PYRIMIDINE À SUBSTITUTION HYDROXYPHÉNYLE, PROCÉDÉS ET PRODUITS INTERMÉDIARES POUR LEUR PRÉPARATION ET MÉDICAMENTS CONTENANT CES COMPOSÉS
  申请人：SOLVAY PHARM GMBH

  公开号：WO2009153261A1

  公开（公告）日：2009-12-23

  Novel compounds are described of the general formula (I), which are selective antagonists of the adenosine A1 receptor and wherein the substituents R1 have the meanings given in the description,and also medicaments containing these compounds, in particular medicaments suitable for treating or preventing cardio-vascular, renal, and/or hepatic disorders or diseases.

  本发明涉及通式（I）的新化合物，其中取代基R1的含义见描述，这些化合物是腺苷A1受体的选择性拮抗剂，并且还涉及包含这些化合物的药物，特别是用于治疗或预防心血管、肾脏和/或肝脏疾病的药物。
• CAPSULES OF ACTIVE PHARMACEUTICAL INGREDIENTS AND POLYUNSATURATED FATTY ACID ESTERS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
  申请人：GP Pharm S.A.

  公开号：EP2501365A2

  公开（公告）日：2012-09-26